Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease

Journal of Clinical Oncology

Volumn 24, Issue 25, 2006, Pages 4116-4122

  Guadagnolo, Beverly A ^a   Punglia, Rinaa S ^a   Kuntz, Karen M ^a   Mauch, Peter M ^a   Ng, Andrea K ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HODGKIN DISEASE; HUMAN; MEDICAL LITERATURE; MEDICARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; EVALUATION; HEALTH SURVEY; LIFE EXPECTANCY; METHODOLOGY; PATHOLOGY; PREDICTION AND FORECASTING; PROBABILITY; RADIOGRAPHY; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COST-BENEFIT ANALYSIS; DACARBAZINE; DECISION SUPPORT TECHNIQUES; DOXORUBICIN; HODGKIN DISEASE; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; NEOPLASM STAGING; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE;

EID: 33748643755     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.0409     Document Type: Article

References (48)

1. Oza AM, Ganesan TS, Leahy M, et al: Patterns of survival in patients with Hodgkin's disease: Long follow up in a single centre. Ann Oncol 4:385-392, 1993
2. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998
3. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054, 1993
4. Josting A, Raemakers JM, Diehl V, et al: New concepts for relapsed Hodgkin's disease. Ann Oncol 13 Suppl 1117-121, 2002
5. Radford JA, Eardley A, Woodman C, et al: Follow up policy after treatment for Hodgkin's disease: Too many clinic visits and routine tests? A review of hospital records. BMJ 314:343-346, 1997
6. Torrey MJ, Poen JC, Hoppe RT: Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies. J Clin Oncol 15:1123-1130, 1997
7. Dryver ET, Jernstrom H, Tompkins K, et al: Follow-up of patients with Hodgkin's disease following curative treatment: The routine CT scan is of little value. Br J Cancer 89:482-486, 2003
8. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993
9. Weinstein MC, Siegel JE, Gold MR, et al: Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276:1253-1258, 1996
10. Bonadonna G, Bonfante V, Viviani S, et al: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22:2835-2841, 2004
11. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
12. Canellos GP, Niedzwiecki D: Long-term follow-up of Hodgkin's disease trial. N Engl J Med 346:1417-1418, 2002
13. Dittmann H, Sokler M, Kollmannsberger C, et al: Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 8:1393-1399, 2001
14. Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999
15. Schaefer NG, Hany TF, Taverna C, et al: Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 232:823-829, 2004
16. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822, 1997
17. Poen JC, Hoppe RT, Horning SJ: High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: The impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 36:3-12, 1996
18. Sureda A, Constans M, Iriondo A, et al: Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16:625-633, 2005
19. Ferme C, Bastion Y, Lepage E, et al: The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 6:543-549, 1995
20. Anselmo AP, Meloni G, Cavalieri E, et al: Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Ann Hematol 79:79-82, 2000
21. Brusamolino E, Orlandi E, Canevari A, et al: Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease. Ann Oncol 5:427-432, 1994
22. Shamash J, Lee SM, Radford JA, et al: Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: A two centre study. Ann Oncol 11:715-719, 2000
23. Sureda A, Arranz R, Iriondo A, et al: Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 19:1395-1404, 2001
24. Ng AK, Weeks JC, Mauch PM, et al: Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: A decision analysis. J Clin Oncol 17:241-252, 1999
25. Ng AK, Weeks JC, Mauch PM, et al: Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease. J Clin Oncol 17:3577-3585, 1999
26. Ng AK, Kuntz KM, Mauch PM, et al: Costs and effectiveness of staging and treatment options in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys 50:979-989, 2001
27. Vellenga E, van Agthoven M, Croockewit AJ, et al: Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: The Hovon 22 study. Br J Haematol 114:319-326, 2001
28. Simnett SJ, Stewart LA, Sweetenham J, et al: Autologous stem cell transplantation for malignancy: A systematic review of the literature. Clin Lab Haematol 22:61-72, 2000
29. Campbell DE, Lynn J, Louis TA, et al: Medicare program expenditures associated with hospice use. Ann Intern Med 140:269-277, 2004
30. Hutchings M, Eigtved AI, Specht L: FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 52:19-32, 2004
31. Schiepers C, Filmont JE, Czernin J: PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30:S82-S88, 2003 (suppl 1)
32. Bangerter M, Moog F, Buchmann I, et al: Whole-body 2-[18F]-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 9:1117-1122, 1998
33. Partridge S, Timothy A, O'Doherty MJ, et al: 2-Fluorine-18-fluoro-2- deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 11:1273-1279, 2000
34. Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al: Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 91:302-310, 2001
35. Jerusalem G, Beguin Y, Fassotte MF, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 86:266-273, 2001
36. Weihrauch MR, Re D, Bischoff S, et al: Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 81:20-25, 2002
37. Menzel C, Dobert N, Mitrou P, et al: Positron emission tomography for the staging of Hodgkin's lymphoma: Increasing the body of evidence in favor of the method. Acta Oncol 41:430-436, 2002
38. Naumann R, Beuthien-Baumann B, Reiss A, et al: Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 90:620-625, 2004
39. Isasi CR, Lu P, Blaufox MD: A metaanalysis of 18F-2-deoxy-2-fluoro-D- glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066-1074, 2005
40. Hicks RJ, Mac Manus MP, Seymour JF: Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 35:165-175, 2005
41. de Wit M, Bohuslavizki KH, Buchert R, et al: 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 12:29-37, 2001
42. Naumann R, Vaic A, Beuthien-Baumann B, et ai: Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 115:793-800, 2001
43. Spaepen K, Stroobants S, Dupont P, et al: Can positron emission tomography with [(18)F1-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 115:272-278, 2001
44. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002
45. Hutchings M, Loft A, Hansen M, et al: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52-59, 2006
46. Jerusalem G, Beguin Y, Fassotte MF, et al: Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14:123-130, 2003
47. NCCN Practice Guidelines in Oncology, Hodgkin's disease/Lymphoma. v1, 2006
48. Expert Panel on Radiation Oncology-Hodgkin's Working Group: Follow-up of Hodgkin's disease. ACR Appropriateness Criteria, 2006